変性椎間板疾患(Degenerative Disc Disease):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Degenerative Disc Disease - Pipeline Review, H2 2014
◆商品コード:GMDHC5813IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:66
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における変性椎間板疾患(Degenerative Disc Disease)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・変性椎間板疾患(Degenerative Disc Disease)の概要
・変性椎間板疾患(Degenerative Disc Disease)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・変性椎間板疾患(Degenerative Disc Disease)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・変性椎間板疾患(Degenerative Disc Disease)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・変性椎間板疾患(Degenerative Disc Disease)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Degenerative Disc Disease – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Degenerative Disc Disease – Pipeline Review, H2 2014’, provides an overview of the Degenerative Disc Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Degenerative Disc Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Degenerative Disc Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Degenerative Disc Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Degenerative Disc Disease Overview 7
Therapeutics Development 8
Pipeline Products for Degenerative Disc Disease – Overview 8
Pipeline Products for Degenerative Disc Disease – Comparative Analysis 9
Degenerative Disc Disease – Therapeutics under Development by Companies 10
Degenerative Disc Disease – Therapeutics under Investigation by Universities/Institutes 11
Degenerative Disc Disease – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Degenerative Disc Disease – Products under Development by Companies 15
Degenerative Disc Disease – Products under Investigation by Universities/Institutes 16
Degenerative Disc Disease – Companies Involved in Therapeutics Development 17
AnGes MG, Inc. 17
Bioheart, Inc. 18
Bone Therapeutics SA 19
DePuy Spine, Inc. 20
Discgenics, Inc 21
ISTO Technologies, Inc. 22
K-Stemcell Co., Ltd. 23
Mesoblast Limited 24
TissueGene, Inc. 25
Yuhan Corporation 26
Degenerative Disc Disease – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AdipoCell – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ALLOB – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
brtxDISC – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CHND-1 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MPC-25-Osteo – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NuQu Cell-Based Therapy – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Poly N-Acetyl Glucosamine Hydrogel – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Recombinant Protein for Degenerative Disc Disease – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
S-414114 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Stem Cell Therapy – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Stem Cell Therapy for Degenerative Disc Disease – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Stem Cell Therapy for Degenerative Disc Disease – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Stem Cell Therapy for Degenerative Disc Disease – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
TG-D – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
YH-14618 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Degenerative Disc Disease – Recent Pipeline Updates 58
Degenerative Disc Disease – Product Development Milestones 63
Featured News & Press Releases 63
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion 63
Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

[List of Tables]
Number of Products under Development for Degenerative Disc Disease, H2 2014 8
Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Comparative Analysis by Unknown Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Degenerative Disc Disease - Pipeline by AnGes MG, Inc., H2 2014 17
Degenerative Disc Disease - Pipeline by Bioheart, Inc., H2 2014 18
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H2 2014 19
Degenerative Disc Disease - Pipeline by DePuy Spine, Inc., H2 2014 20
Degenerative Disc Disease - Pipeline by Discgenics, Inc, H2 2014 21
Degenerative Disc Disease - Pipeline by ISTO Technologies, Inc., H2 2014 22
Degenerative Disc Disease - Pipeline by K-Stemcell Co., Ltd., H2 2014 23
Degenerative Disc Disease - Pipeline by Mesoblast Limited, H2 2014 24
Degenerative Disc Disease - Pipeline by TissueGene, Inc., H2 2014 25
Degenerative Disc Disease - Pipeline by Yuhan Corporation, H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Degenerative Disc Disease Therapeutics - Recent Pipeline Updates, H2 2014 58

[List of Figures]
Number of Products under Development for Degenerative Disc Disease, H2 2014 8
Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Top 10 Targets, H2 2014 28
Number of Products by Stage and Top 10 Targets, H2 2014 29
Number of Products by Top 10 Mechanism of Actions, H2 2014 30
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 31
Number of Products by Top 10 Routes of Administration, H2 2014 32
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 33
Number of Products by Top 10 Molecule Types, H2 2014 34
Number of Products by Stage and Top 10 Molecule Types, H2 2014 35

【掲載企業】

AnGes MG, Inc.
Bioheart, Inc.
Bone Therapeutics SA
DePuy Spine, Inc.
Discgenics, Inc
ISTO Technologies, Inc.
K-Stemcell Co., Ltd.
Mesoblast Limited
TissueGene, Inc.
Yuhan Corporation

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[変性椎間板疾患(Degenerative Disc Disease):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆